The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes

Inclusion Criteria: * Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months prior to randomisation * Body mass index (BMI) between 20.0 and 28.0 kg/m\^2 (both inclusive) Exclusion Criteria: * Use of liraglutide or exenatide within 3 months of randomisation * Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the trial physician or hospitalisation for diabetic ketoacidosis during the previous 6 months * Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening